|Target Name||Product Name||Code||Species||Source||Tag Info|
|N||Recombinant Human Novel Coronavirus Nucleoprotein(N)||CSB-EP3325GMY||SARS-CoV-2||E.coli||N-terminal His-tagged|
|N||Recombinant Human Novel Coronavirus Nucleoprotein(N)||CSB-YP3325GMY||SARS-CoV-2||Yeast||N-terminal His-tagged|
|N||Recombinant Human Novel Coronavirus Nucleoprotein(N)||CSB-BP3325GMY||SARS-CoV-2||Baculovirus||N-terminal His-tagged|
|N||Recombinant Human Novel Coronavirus Nucleoprotein(N)||CSB-MP3325GMY||SARS-CoV-2||Mammalian cell||N-terminal His-tagged|
|S||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-YP3324GMY||SARS-CoV-2||Yeast||N-terminal His-tagged|
|S||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-BP3324GMY||SARS-CoV-2||Baculovirus||N-terminal His-tagged|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-MP3324GMY1||SARS-CoV-2||Mammalian cell||C-terminal 6xHis-mFc-tagged|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-MP3324GMY1b1||SARS-CoV-2||Mammalian cell||N-terminal 10xHis-tagged and C-terminal Myc-tagged|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-YP3324GMY1||SARS-CoV-2||Yeast||N-terminal 6xHis-sumostar-tagged|
|S (S1)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-YP3324GMYa4||SARS-CoV-2||Yeast||N-terminal 6xHis-sumostar-tagged|
|S (S1)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-MP3324GMY||SARS-CoV-2||Mammalian cell||N-terminal 10xHis-tagged and C-terminal Flag-tagged|
|N||Recombinant Human Novel Coronavirus Nucleoprotein(N),partial||CSB-EP3325GMY1||SARS-CoV-2||E.coli|
|N||Recombinant Human Novel Coronavirus Nucleoprotein(N),Biotinylated||CSB-EP3325GMY-B||SARS-CoV-2||E.coli|
|NSP3||Recombinant Severe acute respiratory syndrome coronavirus 2 Non-structural protein 3(nsp3),partial||CSB-EP3398GND||SARS-CoV-2||E.coli|
|NSP5||Recombinant Severe acute respiratory syndrome coronavirus 2 3C-like proteinase(NSP5)||CSB-EP3389GND||SARS-CoV-2||E.coli|
|Nsp9||Recombinant Severe acute respiratory syndrome coronavirus 2 Non-structural protein 9(nsp9)||CSB-MP3388GND||SARS-CoV-2||Mammalian cell|
|Nsp9||Recombinant Severe acute respiratory syndrome coronavirus 2 Non-structural protein 9(nsp9)||CSB-EP3388GND||SARS-CoV-2||E.coli|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V367F), partial||CSB-MP3324GMY1(M1)||SARS-CoV-2||Mammalian cell|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S) (W436R), partial||CSB-MP3324GMY1(M2)||SARS-CoV-2||Mammalian cell|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S) (G476S), partial||CSB-MP3324GMY1(M4)||SARS-CoV-2||Mammalian cell|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S) (N501Y), partial||CSB-MP3324GMY1(M6)||SARS-CoV-2||Mammalian cell|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V483A), partial||CSB-MP3324GMY1(M5)||SARS-CoV-2||Mammalian cell|
|S (RBD)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial,Biotinylated||CSB-MP3324GMY1-B||SARS-CoV-2||Mammalian cell|
|S (S1)||Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial||CSB-YP3324GMYa4||SARS-CoV-2||Yeast|
|S (S1)||Recombinant Human Novel Coronavirus Spike glycoprotein(S) (D614G), partial||CSB-MP3324GMY(M1)||SARS-CoV-2||Mammalian cell|
|S (S1)||Recombinant Human Novel Coronavirus Spike glycoprotein(S)(N501Y,P681H), partial||CSB-MP3324GMY(M2)||SARS-CoV-2||Mammalian cell|
|Product Name||Code||Reactivity Species||Tested Applications|
|N Antibody||CSB-RA33255A1GMY||SARS-CoV-2||ELISA, WB, GICA|
|N Antibody, Biotin conjugated||CSB-RA33255D1GMY||SARS-CoV-2||ELISA|
|N Antibody, FITC conjugated||CSB-RA33255C1GMY||SARS-CoV-2||ELISA|
|N Antibody, HRP conjugated||CSB-RA33255B1GMY||SARS-CoV-2||ELISA|
|S Antibody||CSB-RA33245A1GMY||SARS-CoV-2||ELISA, GICA, Neutralization|
|Spike RBD Nanobody||CSB-RA33245A2GMY||SARS-CoV-2||ELISA, GICA, Neutralization|
|S Antibody, Biotin conjugated||CSB-RA33245D1GMY||SARS-CoV-2||ELISA|
|S Antibody, FITC conjugated||CSB-RA33245C1GMY||SARS-CoV-2||ELISA|
|S Antibody, HRP conjugated||CSB-RA33245B1GMY||SARS-CoV-2||ELISA|
|SARS-CoV-2 RBD Nanobody, Biotin conjugated||CSB-RA33245D2GMY||SARS-CoV-2||ELISA|
|SARS-CoV-2 RBD Nanobody, FITC conjugated||CSB-RA33245C2GMY||SARS-CoV-2||ELISA|
|SARS-CoV-2 RBD Nanobody, HRP conjugated||CSB-RA33245B2GMY||SARS-CoV-2||ELISA|
|SARS-CoV-2 Spike RBD Antibody Pair 1||CSB-EAP33245||SARS-CoV-2||S-ELISA|
|SARS-CoV-2 N Antibody Pair 1||CSB-EAP33255A1||SARS-CoV-2||S-ELISA|
|SARS-CoV-2 N Antibody Pair 2||CSB-EAP33255A2||SARS-CoV-2||S-ELISA|
|SARS-CoV-2 N Antibody Pair 3||CSB-EAP33255A3||SARS-CoV-2||S-ELISA|
|SARS-CoV-2 N Antibody Pair 4||CSB-EAP33255A4||SARS-CoV-2||S-ELISA|
|Product Name||Code||Tested Applications||Raised in|
|S Monoclonal Antibody||CSB-MA33245A0m||GICA||Mouse|
|S Monoclonal Antibody||CSB-MA33245A1m||GICA||Mouse|
|S Monoclonal Antibody||CSB-MA33245A2m||GICA||Mouse|
|Product Name||Code||Sample Types||Assay Principle|
|SARS-CoV-2 N IgG Antibody ELISA Kit||CSB-EL3325HU||serum, plasma||Qualitative|
|SARS-CoV-2 N ELISA Kit||CSB-EL33251||serum, plasma, swabs||Quantitative|
|Human SARS-CoV-2 S RBD Ab (IgG) ELISA Kit||CSB-EL33241HU||serum, plasma||Qualitative|
|Human SARS-CoV-2 S RBD Ab (IgM) ELISA Kit||CSB-EL33242HU||serum, plasma||Qualitative|
|Human SARS-CoV-2 Neutralizing Antibody ELISA Kit||CSB-EL33243HU||serum, plasma||Qualitative|
|Human SARS-CoV-2 N/S1 Ab (IgG) ELISA Kit||CSB-EL3326HU||serum, plasma||Qualitative|
|SARS-CoV-2 S1 RBD ELISA Kit||CSB-EL33244||serum, plasma, swabs||Quantitative|
|Target Name||Product Name||Code||Species||Source||Tag Info|
|HE||Recombinant Bovine coronavirus Hemagglutinin-esterase(HE)||CSB-YP323648BJK||BCoV||Yeast||N-terminal 6xHis-tagged|
|N||Recombinant Bovine coronavirus Nucleoprotein(N)||CSB-EP320768BJK||BCoV||E.coli||N-terminal 6xHis-tagged|
|Orf1ab||Recombinant Middle East respiratory syndrome-related coronavirus Orf1ab,partial||CSB-EP2883GJE||MERS-CoV||E.coli||Tag-Free|
|S||Recombinant Human coronavirus OC43 Spike glycoprotein(S) ,partial||CSB-EP336163HIY||HCoV-OC43||E.coli||N-terminal 6xHis-SUMO-tagged|
|S||Recombinant Human coronavirus OC43 Spike glycoprotein(S) ,partial||CSB-YP336163HIY||HCoV-OC43||Yeast||N-terminal 6xHis-tagged|
|S||Recombinant Bovine coronavirus Spike glycoprotein(S) ,partial||CSB-EP333052BJO||BCoV||E.coli||N-terminal 6xHis-tagged|
|S||Recombinant Bovine coronavirus Spike glycoprotein(S),partial||CSB-EP322803BJK||BCoV||E.coli||N-terminal 10xHis-tagged|
|SARS-COV-RBD||Recombinant Human SARS coronavirus Spike glycoprotein(S) ,partial||CSB-MP348663HQE||SARS-CoV||Mammalian cell|
|Product Name||Code||Sample Types||Detection Range|
|Human ACE2 ELISA Kit||CSB-E04489h||serum, plasma, cell culture supernates||0.156 ng/mL-10 ng/mL|
|Human APN ELISA kit||CSB-EL001827HU||serum, plasma, tissue homogenates||31.25 pg/mL-2000 pg/mL|
|Human CD147 ELISA Kit||CSB-E12994h||serum, plasma||12.5 pg/mL-800 pg/mL|
|Human CTSB ELISA kit||CSB-E13450h||serum, plasma, tissue homogenates||0.312 ng/mL-20 ng/mL|
|Human NRP1 ELISA kit||CSB-EL016091HU||serum, plasma, tissue homogenates||6.25 pg/mL-400 pg/mL|
|Product Name||Code||Species Reactivity||Tested Applications|
|ACE2 Antibody||CSB-PA866317LA01HU||Human||ELISA, IHC, IF|
|ACE2 Antibody||CSB-PA001150GA01HU||Human, Mouse, Rat||ELISA,WB|
|APN Antibody||CSB-PA001827LA01HU||Human, Mouse||ELISA, WB, IHC, IF|
|CD147 antibody||CSB-PA11759A0Rb||Human||ELISA, WB, IHC|
|CTSB Antibody||CSB-PA06974A0Rb||Human, Mouse||ELISA, WB, IHC, IF|
|DPP4 Antibody||CSB-PA06229A0Rb||Human, Rat||ELISA, WB, IHC, IF|
|NRP1 Antibody||CSB-PA016091ESR1HU||Human||ELISA, IHC|
|Target Name||Product Name||Code||Species||Source||Tag Info|
|ACE2||Recombinant Human Angiotensin-converting enzyme 2(ACE2),partial||CSB-AP005671HU||Human||Mammalian cell||C-terminal 6xHis-tagged|
|CD147||Recombinant Human Basigin(BSG),partial||CSB-RP117574h||Human||E.coli||N-terminal 6xHis-tagged|
|CTSB||Recombinant Human Cathepsin B(CTSB),partial (Active)||CSB-AP005381HU||Human||Mammalian cell||C-terminal 6xHis-tagged|
|CTSB||Recombinant Human Cathepsin B(CTSB),partial||CSB-EP006185HU1||Human||E.coli||N-terminal GST-tagged|
|DPP4||Recombinant Human Dipeptidyl peptidase 4(DPP4)||CSB-CF007139HU||Human||in vitro E.coli expression system||N-terminal 10xHis-tagged|
|TMPRSS2||Recombinant Human Transmembrane protease serine 2(TMPRSS2),partial||CSB-EP023924HU||Human||E.coli||N-terminal 6xHis-tagged|
|TMPRSS2||Recombinant Human Transmembrane protease serine 2(TMPRSS2),partial||CSB-YP023924HU||Human||Yeast||N-terminal 6xHis-tagged|
|ACE2||Recombinant Human Angiotensin-converting enzyme 2(ACE2),partial||CSB-MP866317HU||Human||Mammalian cell|
|CD147||Recombinant Human Basigin(BSG),partial||CSB-MP002831HU||Human||Mammalian cell|
|CD147||Recombinant Human Basigin(BSG),partial||CSB-MP002831HUf3||Human||Mammalian cell|
|NUP98||Recombinant Human Nuclear pore complex protein Nup98-Nup96(NUP98) ,partial||CSB-MP016209HU||Human||Mammalian cell|
Based on the fact that the number of infected people in China has increased and outbreaks have occurred in many countries. On January 30, 2020, the World Health Organization announced that the 2019 Novel Coronavirus (SARS-CoV-2) was listed as Public Health Emergency of International Concern (PHEIC). At this point, the SARS-CoV-2 disease (COVID-19) disease is not only a battle in China, but also a global battle. So what exactly is the SARS-CoV-2? How does it spread? Where does SARS-CoV-2 come from? And how to treat it? Don’t worry, we will illustrate these questions one by one.
Before introducing the SARS-CoV-2, let us understand what is a coronavirus. Coronaviruses are a large family of viruses that can cause respiratory illnesses such as the common cold. Almost everyone gets infected with coronaviruses at least once in their life, but symptoms are typically mild to moderate. Most coronaviruses are not dangerous, but some are. Those that cause Middle East respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS) can be deadly.
As the Figure 1 shows, coronaviruses are viruses that are spherical, have protrusions, and are crown-like. They are collectively referred to as coronaviruses. The virus has a diameter of 75 to 160 nanometers, and the virus genome is a continuous linear single-stranded RNA, and the molecular weight is usually (5.5 to 6.1) x106.
The coronavirus genome encodes a spike protein (S), an envelope protein, a membrane protein, and a nucleoprotein in this order. Among them, spike protein is the most important surface membrane protein of coronavirus.
The SARS-CoV-2 was discovered because of Wuhan Viral Pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family in 2003, together with SARS coronavirus (SARS CoV) in 2003 and MERS coronavirus (MERS CoV) in 2012. The alignment between SARS-CoV-2 and 2002 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. There is currently no specific treatment, but many symptoms can be managed, and need to be treated according to the clinical situation of the patient.
CUSABIO paid close attention to the progression of SARS-CoV-2. Once obtaining the virus gene sequence information, we quickly developed and produced SARS-CoV-2 related products. Targets include the Spike protein (S), N protein (N) and ACE2. Moreover, we also provide several products about coronavirus to meet the needs of scientific research.
How does SARS-CoV-2 Spread?
The virus is reportedly spreading from person-to-person in many parts of China and in some other countries by interacting with ACE2 from mucous membrane of eye, mouth and nose. On Jan. 30, the Centers for Disease Control and Prevention (CDC) identified the first case of person-to-person spread in the United States.
In terms of how one would catch the virus, the CDC says that human coronaviruses are most commonly spread between an infected person and others via:
What are The Symptoms of SARS-CoV-2 Infection?
As the Figure 2 shows, the typical symptoms of the SARS-CoV-2 infection include:
It is worth noting that in the course of severe and critically ill patients, there can be moderate to low fever, even without obvious fever. Some patients have mild onset symptoms and no fever. They usually recover after 1 week. Most patients have a good prognosis, and a few patients are critically ill and even die.
Where Does SARS-CoV-2 Come From?
Currently, the origin of SARS-CoV-2 also isn’t clear. But experts suppose that the origin still is wildlife like the other coronaviruses. Coronaviruses originate in animals-like camels, civets and bats-and are usually not transmissible to humans. But occasionally a coronavirus mutates and can pass from animals to humans and then from human to human, as such the case with the SARS epidemic in the early 2000s. China’s National Health Commission confirmed that 15 health care workers have become infected, indicating that the virus can spread from human to human.
Writing here, you may confuse that should I be concerned about pets (such as dog and cat) carring SARS-CoV-2? Exactly, there is no evidence suggested coronavirus in dogs and other pets. But, CDC recommends that people traveling to China avoid animals both live and dead.
How to Treat 2019 Novel Coronavirus?
In terms of SARS-CoV-2 treatment, there are no specific treatments for coronavirus infections and most people will recover on their own. So treatment involves rest and medication to relieve symptoms. A humidifier or hot shower can help to relieve a sore throat and cough. If you are mildly sick, you should drink a lot of fluids and rest.
Although there is no vaccine for the new coronavirus, researchers at the U.S. National Institutes of Health confirmed they were in preliminary stages of developing one. Officials plan to launch a phase 1 clinical trial of a potential vaccine within the next three months. Moreover, researchers are also working on gathering samples of the virus to design a therapy that will train patients’ immune cells to detect and destroy the virus.
How to Protect Yourself From Coronavirus?
Although there are no specific treatment for SARS-CoV-2 infection, we can take these measures to prevent us from it: